- Home
- SHBI vs VERV Comparison
SHBI vs VERV Comparison
Compare SHBI & VERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHBI
- VERV
- Stock Information
- Founded
- SHBI 1876
- VERV 2018
- Country
- SHBI United States
- VERV United States
- Employees
- SHBI N/A
- VERV N/A
- Industry
- SHBI Major Banks
- VERV Medicinal Chemicals and Botanical Products
- Sector
- SHBI Finance
- VERV Health Care
- Exchange
- SHBI Nasdaq
- VERV Nasdaq
- Market Cap
- SHBI 548.7M
- VERV 1.0B
- IPO Year
- SHBI N/A
- VERV 2021
- Fundamental
- Price
- SHBI $15.77
- VERV N/A
- Analyst Decision
- SHBI Buy
- VERV Buy
- Analyst Count
- SHBI 2
- VERV 11
- Target Price
- SHBI $20.00
- VERV $14.57
- AVG Volume (30 Days)
- SHBI 155.3K
- VERV 4.1M
- Earning Date
- SHBI 07-24-2025
- VERV 08-07-2025
- Dividend Yield
- SHBI 3.00%
- VERV N/A
- EPS Growth
- SHBI 169.44
- VERV N/A
- EPS
- SHBI 1.61
- VERV N/A
- Revenue
- SHBI $208,209,000.00
- VERV $59,613,000.00
- Revenue This Year
- SHBI N/A
- VERV $47.32
- Revenue Next Year
- SHBI $7.22
- VERV N/A
- P/E Ratio
- SHBI $9.94
- VERV N/A
- Revenue Growth
- SHBI 24.24
- VERV 271.44
- 52 Week Low
- SHBI $11.47
- VERV $2.87
- 52 Week High
- SHBI $17.61
- VERV $11.41
- Technical
- Relative Strength Index (RSI)
- SHBI 45.41
- VERV 9.97
- Support Level
- SHBI $15.60
- VERV $10.91
- Resistance Level
- SHBI $16.84
- VERV $11.25
- Average True Range (ATR)
- SHBI 0.42
- VERV 0.08
- MACD
- SHBI -0.15
- VERV -1.49
- Stochastic Oscillator
- SHBI 13.71
- VERV 0.00
About SHBI Shore Bancshares Inc
Shore Bancshares Inc is a financial holding company. It offers personalized banking, insurance, and investment services to families and businesses in the Mid-Atlantic region. It operates in one business segment- banking. The company's primary source of revenue is derived from interest earned on commercial, residential mortgage and other loans, and fees charged in connection with lending and other banking services located in Maryland, Delaware and Virginia.
About VERV Verve Therapeutics Inc.
Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The current paradigm of chronic care is fragile requiring rigorous patient adherence, extensive healthcare infrastructure, and regular healthcare access, and leaves many patients without adequate care. Its pipelines are PCSK9, ANGPTL3, and LPA. The group has one reportable segment relating to the research and development of gene-editing medicines. The segment derives its current revenues from research and development collaborations.